Clinical Trial Update: Study of INT-747 in Patients With Diabetes and Presumed NAFLD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for obeticholic acid (INT-747) in patients with type 2 diabetes mellitus and presumed non-alcoholic fatty liver disease; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Obeticholic acid (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Diabetes Mellitus, Type II, Fatty Liver | Phase 2 | Status: COMPLETED | Results posted: 2012-01-27